Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Astrazeneca (AZN) Share News

LONDON MARKET OPEN: Vistry plummets on profit warning, Windward soars

24th Dec 2024 09:01

(Alliance News) - Stock prices in London opened higher on Tuesday, injecting some festive cheer into proceedings as markets prepare to close early on Christmas Eve. Read More

AstraZeneca and Daiichi withdraw EU application for lung cancer drug

24th Dec 2024 08:20

(Alliance News) - AstraZeneca PLC and its Japanese partner Daiichi-Sankyo Co Ltd have withdrawn an application in the European Union for datopotamab deruxtecan for treating certain forms of non-small cell lung cancer. Read More

LONDON BRIEFING: FTSE 100 called up on quiet Christmas half-day

24th Dec 2024 07:57

(Alliance News) - Stocks were called to open in the green on Monday, as markets prepare to close early on Christmas Eve. Read More

LONDON MARKET CLOSE: Stocks end mixed amid unfestive economic backdrop

23rd Dec 2024 17:10

(Alliance News) - Blue chips picked up in late trading to close higher on Monday, but mid-caps faltered as investors assessed a raft of downbeat domestic economic data. Read More

LONDON MARKET MIDDAY: Stocks lack sparkle as data hits festive spirits

23rd Dec 2024 12:08

(Alliance News) - London's FTSE 100 recouped early losses to trade just in the green at midday on Monday although a raft of gloomy economic reports provided little festive cheer. Read More

AstraZeneca receives EU approval for Tagrisso lung cancer treatment

23rd Dec 2024 10:13

(Alliance News) - AstraZeneca PLC on Monday said it has received approval in the European Union for Tagrisso, its non-small cell lung cancer treatment. Read More

LONDON BRIEFING: Lower call as Brits fear "January spending squeeze"

23rd Dec 2024 07:59

(Alliance News) - Stocks in London were called to open down on Monday morning, as investors digest some unwelcome UK economic news at the start of a holiday-shortened week. Read More

PRESS: AstraZeneca sees sales slump in China after arrest of exec - FT

18th Dec 2024 12:44

(Alliance News) - Sales in China have suffered for AstraZeneca PLC after the arrest of its country president, the Financial Times reported on Wednesday, citing "two people familiar with the matter". Read More

LONDON MARKET OPEN: Stocks red as French credit rating gets downgrade

16th Dec 2024 09:00

(Alliance News) - Stock prices in London opened mostly lower on Monday, following another disappointing data release from China. Read More

IN BRIEF: Hutchmed to get Takeda milestone payment

13th Dec 2024 10:04

Hutchmed (China) Ltd - Hong Kong-based biopharmaceutical firm - Is to receive a USD10 million milestone payment from partner Takeda Pharmaceutical Co Ltd. Takeda receives a national reimbursement recommendation for the Fruzaqla cancer treatment in Spain this month. It is the first national reimbursement recommendation in Europe for the drug. "We are delighted for both our partner, Takeda, and patients in Spain who will now be able to receive reimbursement for this innovative treatment. This is an important step forward in improving patient access across Europe more broadly," Hutchmed Chief Executive Officer Weiguo Su says. "It also underscores our ongoing collaboration with Takeda and reinforces our shared commitment to addressing the needs of patients with metastatic colorectal cancer." Read More

IN BRIEF: Merck and AstraZeneca unveil long-term Lynparza results

11th Dec 2024 19:40

Merck & Co Inc and AstraZeneca PLC - Rahway, New Jersey and Cambridge, England-based pharmaceutical firms - Report positive long-term results from phase three OlympiA trial on the use of Lynparza, generic name olaparib, to treat germline BRCA-mutated HER2-negative high-risk early breast cancer. Data showed clinically meaningful improvements in overall survival; invasive disease-free survival and distant disease-free survival, a decrease in the rate of cancer returning and spreading to other organs. After six years, OS rate was 87.5% compared to 83.2% in the placebo group, IDFS rate was 79.6% compared to 70.3% in placebo and DDFS was 83.5% compared to 75.7% in placebo. Lynparza is being jointly developed and commercialized by AstraZeneca and Merck and has been approved in the US, EU and Japan, among others. The EU indication also includes patients with locally advanced breast cancer. Read More

AstraZeneca, Daiichi Sankyo hail US breakthrough therapy designation

9th Dec 2024 09:09

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Monday announced they have been granted a breakthrough therapy designation in the US to treat some sufferers of non-small cell lung cancer. Read More

LONDON BRIEFING: boohoo gets ISS backing amid Frasers Group spat

9th Dec 2024 07:51

(Alliance News) - London's FTSE 100 is called higher, while stocks in Hong Kong perked up amid after a slow start amid fresh hope for the Chinese economy. Read More

EARNINGS AND TRADING: Synectics deal wins; TruFin to beat expectations

5th Dec 2024 19:52

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More

LONDON MARKET CLOSE: Stocks mixed, French political drama continues

5th Dec 2024 17:03

(Alliance News) - Stock prices in London closed mixed on Thursday, ahead of key US data on Friday. Read More

AstraZeneca touts US FDA approval for small cell lung cancer treatment

5th Dec 2024 09:46

(Alliance News) - AstraZeneca PLC on Thursday said the US Food & Drug Administration has approved its Imfinzi treatment for adults with limited-stage small cell lung cancer. Read More

TOP NEWS: AstraZeneca appoints replacement for detained China boss

4th Dec 2024 21:37

(Alliance News) - AstraZeneca PLC on Wednesday appointed Iskra Reic as its new international executive vice president, replacing Leon Wang, who has been detained by Chinese authorities. Read More

LONDON MARKET CLOSE: Blue-chips in the red despite European, US gains

4th Dec 2024 17:17

(Alliance News) - Stocks in London ended mixed on Wednesday, with the FTSE 100 held back by falls in AstraZeneca plus uninspiring data, while mid-caps prospered amid rate cut hopes. Read More

LONDON MARKET MIDDAY: FTSE 100 underperforms before US jobs data

4th Dec 2024 12:10

(Alliance News) - London's FTSE 100 faltered, but European peers climbed and US stocks are called to open higher, with focus turning to US jobs data and the outcome of a key vote over in France. Read More

TOP NEWS: AstraZeneca hails positive Truqap data on prostate cancer

25th Nov 2024 08:51

(Alliance News) - AstraZeneca PLC on Monday said its Truqap combination in a type of prostate cancer showed a statistically significant improvement in a form of progression-free survival. Read More

FTSE 100 Latest
Value8,809.74
Change53.53